Drug Profile


Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; Posiphen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Cenomed BioSciences; QR Pharma; Rockefeller University; University of California at Los Angeles
  • Class Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
  • Preclinical Huntington's disease
  • No development reported Brain injuries; Poisoning

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Poisoning in USA (PO)
  • 16 Mar 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease and Parkinson's disease released by QR Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top